Zydus Lifesciences Limited — Others, 16-04-2025: Rumour Verification - Regulation 30(11)

Zydus Lifesciences has informed that a U.S. District Court ruled against the company regarding a patent litigation involving Astellas Pharma's Myrbetriq® (mirabegron). This decision could lead to significant implications for Zydus's operations, as the validity of the patent may affect their ability to market a generic version. The company is assessing the potential impact and exploring legal remedies. This development has caused notable volatility in the company's share price, presenting a scenario that investors should closely monitor, considering both the risks of patent disputes and potential future strategies in the market.